Published in Respir Res on January 19, 2017
The Challenges of Precision Medicine in COPD. Mol Diagn Ther (2017) 0.75
Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ (1992) 26.37
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 3.69
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA (2013) 2.59
Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 2.58
Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med (1997) 2.55
Early life origins of chronic obstructive pulmonary disease. Thorax (2009) 2.20
Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med (2009) 2.04
Pulmonary emphysema: objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry. Radiology (2006) 1.93
Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med (2007) 1.85
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.82
The role of neutrophil elastase in acute lung injury. Eur J Pharmacol (2002) 1.62
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med (2015) 1.60
Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest (2012) 1.55
Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J (2016) 1.54
The role of extracellular matrix quality in pulmonary fibrosis. Respiration (2014) 1.46
The effect of secondhand smoke exposure on markers of elastin degradation. Chest (2011) 1.41
Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis (2008) 1.41
The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxygen and exercise. Am Rev Respir Dis (1983) 1.40
Series "matrix metalloproteinases in lung health and disease": Matrix metalloproteinases in COPD. Eur Respir J (2011) 1.33
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.29
Elastin content of normal and emphysematous lung parenchyma. Am J Med (1980) 1.26
Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? Clin Biochem (2010) 1.25
Tropoelastin. Int J Biochem Cell Biol (2008) 1.23
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assay. PLoS One (2011) 1.19
Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol (2006) 1.17
A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers (2011) 1.16
Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest (2014) 1.15
Altered fibroblast proteoglycan production in COPD. Respir Res (2010) 1.14
Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogenesis Tissue Repair (2011) 1.11
Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun (2014) 1.10
Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2016) 1.07
Elastin expression in very severe human COPD. Eur Respir J (2009) 1.06
Neutrophil elastase-mediated lung disease. COPD (2013) 1.02
Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights (2012) 0.99
Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med (2012) 0.94
Evaluation of elastase and antielastase balance in patients with chronic bronchitis and pulmonary emphysema. Am Rev Respir Dis (1990) 0.94
Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair (2011) 0.94
Fibrotic response of tissue remodeling in COPD. Lung (2011) 0.92
Acute effect of smoking on the functional activity of alpha1-protease inhibitor in bronchoalveolar lavage fluid. Am Rev Respir Dis (1985) 0.91
Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open (2013) 0.91
The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res (2014) 0.88
Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med (2013) 0.87
MMP mediated type V collagen degradation (C5M) is elevated in ankylosing spondylitis. Clin Biochem (2012) 0.86
Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways -- implications for modern clinical chemistry. Biomarkers (2013) 0.86
The natural history of chronic bronchitis. Community Health (Bristol) (1975) 0.86
Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther (2014) 0.84
Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther (2014) 0.84
Characterization of peptide fragments from lung elastin degradation in chronic obstructive pulmonary disease. Exp Lung Res (2010) 0.83
Collagen Type III and VI Turnover in Response to Long-Term Immobilization. PLoS One (2015) 0.82
Progression from Asthma to Chronic Obstructive Pulmonary Disease. Is Air Pollution a Risk Factor? Am J Respir Crit Care Med (2016) 0.81
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81
Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. Chest (2015) 0.80
Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders. Clin Biochem (2015) 0.80
Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling. BMC Pulm Med (2015) 0.79
Tissue turnover of collagen type I, III and elastin is elevated in the PCLS model of IPF and can be restored back to vehicle levels using a phosphodiesterase inhibitor. Respir Res (2016) 0.78
Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res (2015) 0.78
Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.78
Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. Chest (2016) 0.77
Characterization of serological neo-epitope biomarkers reflecting collagen remodeling in clinically stable chronic obstructive pulmonary disease. Clin Biochem (2016) 0.77
Alpha1-antitrypsin deficiency: a clinical-genetic overview. Appl Clin Genet (2011) 0.77
High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Respir Res (2016) 0.76
New treatments for COPD: many miles still to go. Lancet Respir Med (2013) 0.75